Video

HEM-ONC CHAT: What Research Area is on Top of Your Agenda?

Publish date: December 10, 2012

 

We asked attendees at the annual meeting of the American Society of Hematology what research topics were of most interest to them at the meeting. Follow our ongoing coverage of #ASH12 at http://www.oncologyreport.com.

Recommended Reading

FDA Approves Marqibo for Acute Lymphoblastic Leukemia
MDedge Hematology and Oncology
MS Use Leads to Free Campath for Leukemia Patients
MDedge Hematology and Oncology
FDA Approves Bosutinib for Previously Treated CML
MDedge Hematology and Oncology
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
MDedge Hematology and Oncology
ASRM: Egg Freezing No Longer 'Experimental'
MDedge Hematology and Oncology
FDA Approves Omacetaxine for Chronic Myeloid Leukemia
MDedge Hematology and Oncology
Melanoma Treatment With Vemurafenib Can Trigger Leukemia
MDedge Hematology and Oncology
Dasatinib in the first-line treatment of chronic myeloid leukemia
MDedge Hematology and Oncology
Late Leukemia Risk Rises after Breast Cancer Therapy
MDedge Hematology and Oncology
FDA approves 3rd-generation TKI for CML
MDedge Hematology and Oncology